1
Clinical Trials associated with 1031A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
This study was designed to evaluate the effect of two dose levels of NUC-1031 (500 mg/m2 and 750mg/m2) in patients with ovarian cancer. The primary objective was to determine the anti-tumor activity of NUC-1031 at the selected dose level (500 mg/m2 or 750 mg/m2).
100 Clinical Results associated with 1031
100 Translational Medicine associated with 1031
100 Patents (Medical) associated with 1031
100 Deals associated with 1031